{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:58Z","timestamp":1786982398205,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Randomised clinical trials (RCTs) are vital for medical progress. Unfortunately, \u2018traditional\u2019 RCTs are expensive and inherently slow. Moreover, their generalisability has been questioned. There is considerable overlap in routine health care data (RHCD) and trial-specific data. Therefore, integration of RHCD in an RCT has great potential, as it would reduce the effort and costs required to collect data, thereby overcoming some of the major downsides of a\u00a0traditional RCT. However, use of RHCD comes with other challenges, such as privacy issues, as well as technical and practical barriers. Here, we give a\u00a0current overview of related initiatives on national cardiovascular registries (Netherlands Heart Registration, Heart4Data), showcasing the interrelationships between and the relevance of the different registries for the practicing physician. We then discuss the benefits and limitations of RHCD use in the setting of a\u00a0pragmatic RCT from a\u00a0cardiovascular perspective, illustrated by a\u00a0case study in heart failure.<\/jats:p>","DOI":"10.1007\/s12471-023-01837-5","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T06:02:11Z","timestamp":1705298531000},"page":"106-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Embedding routine health care data in clinical trials: with great power comes great responsibility"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-7865","authenticated-orcid":false,"given":"M. Louis","family":"Handoko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances S.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J.","family":"Brugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke F. M.","family":"Rhodius-Meester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J. Rik","family":"van de Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Houterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"van Veghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Uijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1056\/NEJMsb1901642","volume":"382","author":"R Collings","year":"2020","unstructured":"Collings\u00a0R, Bowman\u00a0L, Landray\u00a0M, Peto\u00a0R. The magic of randomization versus the myth of real-world evidence. N\u00a0Engl J Med. 2020;382:674\u20138.","journal-title":"N Engl J Med"},{"key":"1837_CR2","doi-asserted-by":"crossref","first-page":"e43906","DOI":"10.1136\/bmjopen-2020-043906","volume":"11","author":"MR Sydes","year":"2021","unstructured":"Sydes\u00a0MR, Barbachano\u00a0Y, Bowman\u00a0L, et al. The Data Enabled Trials Group Workshop Group members. Realising the full potential of data-enabled trials in the UK: a\u00a0call for action. BMJ Open. 2021;11:e43906.","journal-title":"BMJ Open"},{"key":"1837_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12471-022-01672-0","volume":"30","author":"MJC Timmermans","year":"2022","unstructured":"Timmermans\u00a0MJC, Houterman\u00a0S, Daeter\u00a0ED, et al. PCI Registration Committee of the Netherlands Heart Registration and the Cardiothoracic Surgery Registration Committee of the Netherlands Heart Registration. Using real-world data to monitor and improve quality of care in coronary artery disease: results from the Netherlands Heart Registration. Neth Heart\u00a0J. 2022;30:546\u201356.","journal-title":"Neth Heart J"},{"key":"1837_CR4","doi-asserted-by":"publisher","first-page":"e36220","DOI":"10.1136\/bmjopen-2019-036220","volume":"10","author":"G Chu","year":"2020","unstructured":"Chu\u00a0G, Seelig\u00a0J, Trinks-Roerdink\u00a0EM, et al. Design and rationale of DUTCH-AF: a\u00a0prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. BMJ Open. 2020;10:e36220.","journal-title":"BMJ Open"},{"key":"1837_CR5","unstructured":"Dutch CardioVascular Alliance. https:\/\/dcvalliance.nl\/heart4data. Accessed 17\u00a0May 2023."},{"key":"1837_CR6","unstructured":"RECOVERY trial, University of Oxford. https:\/\/www.recoverytrial.net. Accessed 24\u00a0Jan 2022."},{"key":"1837_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, et\u00a0al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1837_CR8","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","volume":"374","author":"DA Konstam","year":"2009","unstructured":"Konstam\u00a0DA, Neaton\u00a0JD, Dickstein\u00a0K, et al. HEAAL investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a\u00a0randomised, double-blind trial. Lancet. 2009;374:1840\u20138.","journal-title":"Lancet"},{"key":"1837_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan\u00a0M, Claggett\u00a0BL, Jhund\u00a0PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a\u00a0comparative analysis of three randomised controlled trials. Lancet. 2020;396:121\u20138.","journal-title":"Lancet"},{"key":"1837_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a\u00a0multinational, open-label, randomised, trial. Lancet. 2022;400:1938\u201352.","journal-title":"Lancet"},{"key":"1837_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13063-016-1354-9","volume":"17","author":"T Aung","year":"2016","unstructured":"Aung\u00a0T, Haynes\u00a0R, Barton\u00a0J, et al. ASCEND Study Collaborative Group. Cost-effective recruitment methods for a\u00a0large randomised trial in people with diabetes: A\u00a0Study of Cardiovascular Events iN Diabetes (ASCEND). Trials. 2016;17:286.","journal-title":"Trials"},{"key":"1837_CR12","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/ehac179","volume":"43","author":"S Parish","year":"2022","unstructured":"Parish\u00a0S, Mafham\u00a0M, Offer\u00a0A, et\u00a0al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur Heart\u00a0J. 2022;43:2010\u20139.","journal-title":"Eur Heart J"},{"key":"1837_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ehjqcco\/qcy034","volume":"4","author":"E Wierda","year":"2018","unstructured":"Wierda\u00a0E, Eindhoven\u00a0DC, Schalij\u00a0MJ, et al. Privacy of patient data in quality-of-care registries in cardiology and cardiothoracic surgery: the impact of the new general data protection regulation EU-law. Eur Heart J Qual Care Clin Outcomes. 2018;4:239\u201345.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1837_CR14","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1016\/j.vaccine.2012.04.056","volume":"30","author":"JG Berry","year":"2012","unstructured":"Berry\u00a0JG, Ryan\u00a0P, Gold\u00a0MS, Ryana\u00a0P, Duszynski\u00a0KM, Braunack-Mayer\u00a0AJ. for the VALiD working group. Public perspectives on consent for the linkage of data to evaluate vaccine safety. Vaccine. 2012;30:4167\u201374.","journal-title":"Vaccine"},{"key":"1837_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canep.2018.12.005","volume":"58","author":"JM Elwood","year":"2019","unstructured":"Elwood\u00a0JM, Marshall\u00a0RJ, Tin\u00a0TS, Barrios\u00a0MEP, Harvey\u00a0VJ. Bias in survival estimates created by a\u00a0requirement for consent to enter a\u00a0clinical breast cancer registry. Cancer Epidemiol. 2019;58:178\u201383.","journal-title":"Cancer Epidemiol"},{"key":"1837_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/medethics-2011-100145","volume":"38","author":"JG Berry","year":"2012","unstructured":"Berry\u00a0JG, Ryan\u00a0P, Gold\u00a0MS, Braunack-Mayer\u00a0AJ, Duszynski\u00a0KM. for the VALiD working group. A\u00a0randomised controlled trial to compare opt-in and opt-out parental consent for childhood vaccine safety surveillance using data linkage. J\u00a0Med Ethics. 2012;38:619\u201325.","journal-title":"J Med Ethics"},{"key":"1837_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/intqhc\/mzx196","volume":"30","author":"DMD Emdadul Hoque","year":"2018","unstructured":"Emdadul Hoque\u00a0DMD, Ruseckaite\u00a0R, Lorgelly\u00a0P, McNeil\u00a0JJ, Evans\u00a0SM. Cross-sectional study of characteristics of clinical registries in Australia: a\u00a0resource for clinicians and policy makers. Int J Qual Health Care. 2018;30:192\u20139.","journal-title":"Int J Qual Health Care"},{"key":"1837_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/HCM.0000000000000302","volume":"39","author":"EJ Layman","year":"2020","unstructured":"Layman\u00a0EJ. Ethical issues and the electronic health record. Health Care Manag. 2020;39:150\u201361.","journal-title":"Health Care Manag"},{"issue":"Suppl 2","key":"1837_CR19","doi-asserted-by":"publisher","first-page":"O68","DOI":"10.1186\/1745-6215-16-S2-O68","volume":"16","author":"L Adamska","year":"2015","unstructured":"Adamska\u00a0L, Allen\u00a0N, Flaig\u00a0R, Sudlow\u00a0C, Lay\u00a0M, Landray\u00a0M. Challenges of linking to routine healthcare records in UK Biobank. Trials. 2015;16(Suppl 2):O68.","journal-title":"Trials"},{"key":"1837_CR20","doi-asserted-by":"crossref","unstructured":"McCall B. Data, data all around. Lancet Digit Health. 2021;3:e284\u20135.","DOI":"10.1016\/S2589-7500(21)00063-7"},{"key":"1837_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2009.09.010","volume":"46","author":"MPP van Herk-Sukel","year":"2010","unstructured":"van Herk-Sukel\u00a0MPP, van de Poll-Franse\u00a0LV, Lemmens\u00a0VEPP, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010;46:395\u2013404.","journal-title":"Eur J Cancer"},{"key":"1837_CR22","doi-asserted-by":"publisher","first-page":"e2139748","DOI":"10.1001\/jamanetworkopen.2021.39748","volume":"4","author":"C Harper","year":"2021","unstructured":"Harper\u00a0C, Mafham\u00a0M, Herrington\u00a0W, et al. Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial-adjudicated direct follow-up data in the UK: secondary analysis of the ASCEND randomized clinical trial. Jama Netw Open. 2021;4:e2139748.","journal-title":"Jama Netw Open"},{"key":"1837_CR23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jamacardio.2016.3236","volume":"1","author":"S Blecker","year":"2016","unstructured":"Blecker\u00a0S, Katz\u00a0SD, Horwitz\u00a0LIO, et\u00a0al. Comparison of approaches for heart failure case identification from electronic health record data. JAMA Cardiol. 2016;1:1014\u201320.","journal-title":"JAMA Cardiol"},{"key":"1837_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","volume":"375","author":"J Vestbo","year":"2016","unstructured":"Vestbo\u00a0J, Leather\u00a0D, Diar Bakerly\u00a0N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N\u00a0Engl J Med. 2016;375:1253\u201360.","journal-title":"N Engl J Med"},{"key":"1837_CR25","unstructured":"Netherlands Heart Registration. NHR Rapportage. https:\/\/www.hartenvaatcijfers.nl\/nhr-rapportage. Accessed 12\u00a0Dec 2022."},{"key":"1837_CR26","first-page":"272","volume":"26","author":"JJ Brugts","year":"2018","unstructured":"Brugts\u00a0JJ, Linssen\u00a0GCM, Hoes\u00a0AW, Brunner-La\u00a0RHP, CHECK-HF investigators. Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: Design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. Neth Heart\u00a0J. 2018;26:272\u20139.","journal-title":"CHECK-HF) registry. Neth Heart\u00a0J."},{"key":"1837_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-022-01752-1","author":"S Houterman","year":"2023","unstructured":"Houterman S, van Dullemen A, Versteegh M, et al., PCI Registration Committee of the Netherlands Heart Registration. Data quality and auditing within the Netherlands Heart Registration: using the PCI registry as an example. Neth Heart J. 2023;31 https:\/\/doi.org\/10.1007\/s12471-022-01752-1.","journal-title":"Neth Heart J"},{"key":"1837_CR28","unstructured":"Jun. 2023. https:\/\/dcvalliance.nl\/files\/files\/NHR-H4D-factsheet-voor-centra_Folder_A5_DCVA_2022_V5_AG.pdf. Accessed 2021."},{"key":"1837_CR29","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1093\/eurheartj\/ehac426","volume":"43","author":"D Kotecha","year":"2022","unstructured":"Kotecha\u00a0D, Asselbergs\u00a0FW, Achenbach\u00a0S, et al. Innovative Medicines Initiative BigData@Heart Consortium, European Society of Cardiology, CODE-EHR international consensus group. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research. Eur Heart\u00a0J. 2022;43:3578\u201388.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01837-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-023-01837-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01837-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:23:26Z","timestamp":1708590206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-023-01837-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1007\/s12471-023-01837-5","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"6 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.\u00a0Handoko received an educational grant from Novartis and Boehringer Ingelheim, and speaker\/consultancy fees from Novartis, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, AstraZeneca, Bayer, MSD, Abbott and Quin, all not related to this work. F.S.\u00a0de Man is currently Associate Editor of the <i>Netherlands Heart Journal<\/i>. J.J.\u00a0Brugts received speaker\/consultancy fees from Bayer, Novartis, Abbott and Vifor Pharma, all not related to this work. He is currently Associate Editor of the <i>Netherlands Heart Journal<\/i>. P.\u00a0van der Meer received consultancy fees and\/or grants from Novartis, Pharmacosmos, Vifor Pharma, AstraZeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk and Ionis, paid to the institute. H.F.M.\u00a0Rhodius-Meester performs contract research for Combinostics; all funding is paid to her institution. J.\u00a0Schaap received an educational grant and speaker\/consultancy fees from Boehringer Ingelheim, Daiichi Sankyo, AstraZeneca, General Electric and Novo Nordisk, all not related to this work. H.J.\u00a0R.\u00a0van de Kamp, S.\u00a0Houterman, D.\u00a0van Veghel, A.\u00a0Uijl and F.W.\u00a0Asselbergs declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}